Targeting the central nervous system inflammatory response in ischemic stroke

Current Opinion in Neurology

Volumn 14, Issue 3, 2001, Pages 349-353

  Becker, Kyra J ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYTOKINE; EXCITOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; HUMAN; INFLAMMATION; LEUKOCYTE; NONHUMAN; REVIEW; STROKE;

ANIMALS; AUTOANTIGENS; BLOOD-BRAIN BARRIER; CEREBRAL INFARCTION; CYTOKINES; ENCEPHALITIS; HUMANS; LEUKOCYTES; MYELIN BASIC PROTEINS;

EID: 0034989884     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200106000-00014     Document Type: Review

References (68)

1. Inducible nitric oxide synthase expression in human cerebral infarcts
2. Poly(ADP-ribose) synthase inhibition reduces ischemic injury and inflammation in neonatal rat brain
3. Neutrophil elastase inhibition reduces cerebral ischemic damage in the middle cerebral artery occlusion
4. The enlimomab acute stroke trial: Final results
5. Some potentially harmful side effects of anti-ICAM-1 antibody administration in preclinical animal studies of stroke
6. Inhibition of alpha-4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats
7. Antibody to the alpha 4 integrin decreases infarct size in transient focal cerebral ischemia in rats
8. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury
9. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation
10. Effects of poststroke pyrexia on stroke outcome: A meta-analysis of studies in patients
11. Proinflammatory cytokines and early neurological worsening in ischemic stroke
12. Effects of delayed intraischemic and postischemic hypothermia on a focal model of transient cerebral ischemia in rats
13. Importance of posttraumatic hypothermia and hyperthermia on the inflammatory response after fluid percussion brain injury: Biochemical and immunocytochemical studies
14. Effect of moderate hypothermia on systemic and internal jugular plasma IL-6 levels after traumatic brain injury in humans
15. Treatment of traumatic brain injury with moderate hypothermia
16. Temporal modulation of cytokine expression following focal cerebral ischemia in mice
17. Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice
18. Quantitative changes in interleukin proteins following focal stroke in the rat
19. The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke
20. Ischemia-induced inteleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitotoxicity in the brain
21. Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways
22. Interleukin-6 (IL-6): A molecule with both beneficial and destructive potentials
23. Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat
24. IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage
25. Overexpression of interleukin-6 in the central nervous system of transgenic mice increases central but not systemic proinflammatory cytokine production
26. Expression of IL-6 in the ischemic penumbra
27. Time course of IL-6 expression in experimental CNS ischemia
28. Cortisol axis abnormalities early after stroke-relationships to cytokines and leptin
29. Interaction between interleukin-6 and the natural anticoagulant system in acute stroke
30. Lack of interleukin-6 expression is not protective against focal central nervous system ischemia
31. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia
32. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: A possible role in blood-brain barrier dysfunction
33. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion
34. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke
35. Role for matrix metalloproteinase 9 after focal cerebral ischemia: Effects of gene knockout and enzyme inhibition with BB-94
36. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo
37. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium
38. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-kappa B
39. Matrix metalloproteinases of human NK cells
40. Microglial activation and neurological symptoms in the SIV model of NeuroAIDS: Association of MHC-II and MMP-9 expression with behavioral deficits and evoked potential changes
41. Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors
42. Matrix metalloprotease-9 release from monocytes increases as a function of differentiation: Implications for neuroinflammation and neurodegeneration
43. Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke
44. Do transient ischemic attacks have a neuroprotective effect?
45. Effects of lipopolysaccharide priming on acute ischemic brain injury
46. Induction of tolerance against ischemia/reperfusion injury in the rat brain by preconditioning with the endotoxin analog diphosphoryl lipid A
47. Cutting edge: Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression
48. Increase in endogenous brain superoxide dismutase as a potential mechanism of lipopolysaccharide-induced brain ischemic tolerance
49. Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice
50. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy
51. Murine models define the role of TGF-beta as a master regulator of immune cell function
52. TGF-β1 protects hippocampal neurons against degeneration caused by transient global ischemia. Dose-response relationship and potential neuroprotective mechanisms
53. Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice
54. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation
55. Cortical death caused by striatal administration of AMPA and interleukin-1 is mediated by activation of cortical NMDA receptors
56. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy
57. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion
58. Production of neurotrophins by activated T cells: Implications for neuroprotective autoimmunity
59. Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia
60. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
61. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
62. Serum C-reactive protein and self-reported stroke: Findings from the Third National Health and Nutrition Examination Survey
63. Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study
64. Long-term effects of pravastatin on plasma concentration of C-reactive protein
65. Pravastatin therapy and the risk of stroke
66. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
67. Adhesion molecules in cerebrovascular diseases. Evidence for an inflammatory endothelial activation in cerebral large- and small-vessel disease